Sotagliflozin Significantly Reduces Cardiovascular Risk in high risk patients.
Sotagliflozin Significantly Reduces Cardiovascular Risk in high risk patients.
Published originally in: The Lancet Diabetes & Endocrinology, AHA publications Feb 19 2025.
A new study published in The Lancet Diabetes & Endocrinology highlights that sotagliflozin, a dual SGLT1/SGLT2 inhibitor, significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes, chronic kidney disease (CKD), and additional cardiovascular risk factors.
Key Findings:
• The study followed 10,000+ patients randomly assigned to either sotagliflozin or placebo for a median of 14 months.
• Sotagliflozin reduced MACE risk by 23%, including myocardial infarction, stroke, and cardiovascular death.
• There were also significant reductions in individual risks of myocardial infarction and stroke.
• Unlike other SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin), sotagliflozin demonstrated a more pronounced reduction in MACE risk, marking a potential breakthrough in cardiovascular protection.
Clinical Implications:
• Sotagliflozin offers a new treatment option to reduce cardiovascular risks in patients with heart failure, type 2 diabetes, and CKD.
• Approved by the FDA in 2023 for heart failure, the drug is now positioned for expanded clinical use.
• According to Deepak L. Bhatt, MD, MPH, MBA, director of Mount Sinai Fuster Heart Hospital, these findings support wider adoption of sotagliflozin for reducing cardiovascular mortality, hospitalizations for heart failure, and urgent heart failure visits.
This study reinforces sotagliflozin’s role as a valuable therapeutic option for high-risk cardiovascular patients.
Reference: